A first vaccine based on adjuvanted purified excreted/secreted antigens of L. infantum was initially licensed in Europe in 2011. This vaccine contained a saponin adjuvant. Currently it is not commercially available.
The only currently available vaccine in Europe contains the active substance “protein Q”, a recombinant protein containing five different antigens from L. infantum without an additional adjuvant. First vaccination is a single injection. Booster injections are given annually.
The vaccine available in Europe can only be injected to healthy quantitatively seronegative dogs of 6 months of age or older. Vaccine does not prevent infection, but does alter disease progression and probability of progression to clinically overt disease.
Anti-Leishmania available vaccines
|Commercial name (manufacturer)||Composition||Availability||Vaccine protocol||Primary outcome||Vaccine efficacy||Diagnostic interference associated w/vaccine|
|Leish-Tec® (Ceva Santé Animale)||A2||Saponin||Brazil||Three primary vaccination doses (SC), 21-day intervals; one annual booster||Parasite detection||71.4%||No detection of vaccinal antibodies with official ELISA*|
|Letifend® (Leti Pharma laboratories)||Q-protein||None||Europe||One primary vaccination dose (SC); one annual booster||Clinical disease||72%||No detection of vaccinal antibodies by quantitative tests (IFAT, ELISA) or Serology rapid tests|
*Elicited antibodies against A2 protein are not detected by official serological tests employed in Brazil.